GDTC

CytoMed Therapeutics Limited (NASDAQ:GDTC) is a Singapore-based pre-clinical biopharmaceutical company founded in 2018 that specializes in developing novel cell-based immunotherapies for cancer treatment. The company went public in April 2023 and focuses on harnessing the power of gamma delta T cells and other immune cells to create innovative cancer treatments. As a pre-clinical stage company, CytoMed is currently developing its pipeline of experimental therapies without any approved products on the market.